Core Viewpoint - Rapport Therapeutics reported strong progress in its precision neuroscience pipeline, particularly with the lead program RAP-219 for epilepsy, which is expected to have a significant market opportunity if approved [2][6]. Financial Results - The company reported a net loss of $33.8 million for Q4 2025, compared to a loss of $20.0 million in Q4 2024. For the full year 2025, the net loss was $111.5 million, up from $78.3 million in 2024 [12][18]. - Research and Development (R&D) expenses for Q4 2025 were $30.3 million, an increase from $17.2 million in Q4 2024. For the full year, R&D expenses totaled $94.8 million, compared to $60.9 million in 2024 [12][13]. - General and Administrative (G&A) expenses for Q4 2025 were $8.3 million, up from $6.3 million in Q4 2024. For the full year, G&A expenses were $30.3 million, compared to $22.1 million in 2024 [12][13]. Pipeline Developments - RAP-219 demonstrated robust activity in patients with focal onset seizures (FOS) during the Phase 2a trial, with a median reduction in clinical seizure frequency of 77.8% and 72% of patients achieving a ≥50% reduction in seizures [6][5]. - The company plans to initiate a Phase 3 program for RAP-219 in FOS in Q2 2026, accelerated from previous guidance [7][6]. - Rapport is expanding its epilepsy portfolio to include primary generalized tonic-clonic seizures (PGTCS) based on the Phase 2a data from FOS [11][5]. Strategic Collaborations - In March 2026, the company entered a strategic collaboration with Tenacia Biotechnology to develop and commercialize RAP-219 in Greater China, which includes an upfront payment of $20 million and potential milestone payments totaling approximately $308 million [9][5]. Cash Position - As of December 31, 2025, the company had $490.5 million in cash, cash equivalents, and short-term investments, which is expected to fund operations into the second half of 2029 [18][12].
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update